EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

End-to-End Continuous Small-Scale Drug Substance Manufacturing: From a Continuous In Situ Nucleator to Free-Flowing Crystalline Particles

Anne Cathrine Kufner, Marc Meier, Kerstin Wohlgemuth

Crystals · 11.12.2023 · 13 (12) · 1675

DOI: 10.3390/cryst13121675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crystals, online erschienen am 11.12.2023. Verfasst von Anne Cathrine Kufner und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation (Deutsche Forschungsgemeinschaft—DFG) in the framework of the Priority Programme SPP 2364.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the evolving landscape of pharmaceutical manufacturing, a comprehensive continuous production process is being crafted for the small-scale production of active pharmaceutical ingredients. This study focuses on continuous crystallization with separate nucleation and crystal growth units, as well as continuous downstream processing, encompassing filtration, washing, and drying until the formation of free-flowing particles. We introduce a novel continuous nucleator designed based on solubility data and produced via 3D printing, enabling the fast and precise small-scale manufacturing of a nucleator meeting the requirements for nucleation and further growth processes. The nucleator is evaluated with regard to its suitability for continuous long-term operation across various coupled crystallizers. As a practical application example, it is connected to a slug flow crystallizer to enable high-quality continuous crystallization. Additionally, the full integration of downstream processes using a continuous vacuum screw filter to achieve free-flowing product particles is realized. Even under non-optimized process conditions, with the help of the in situ generation of nuclei, free-flowing product particles are successfully obtained. This is particularly useful during drug development when no material is available for seed addition and to quickly obtain products for further characterization.

Förderung

  • German Research Foundation (Deutsche Forschungsgemeinschaft—DFG) in the framework of the Priority Programme SPP 2364

Zitieren

APA

Kufner, A. C., Meier, M., & Wohlgemuth, K. (2023). End-to-End Continuous Small-Scale Drug Substance Manufacturing: From a Continuous In Situ Nucleator to Free-Flowing Crystalline Particles. Crystals, 13(12), 1675. https://doi.org/10.3390/cryst13121675

Vancouver

Kufner AC, Meier M, Wohlgemuth K. End-to-End Continuous Small-Scale Drug Substance Manufacturing: From a Continuous In Situ Nucleator to Free-Flowing Crystalline Particles. Crystals. 2023;13(12):1675. doi:10.3390/cryst13121675

BibTeX
@article{Kufner2023,
  author = {Kufner, Anne Cathrine and Meier, Marc and Wohlgemuth, Kerstin},
  title = {End-to-End Continuous Small-Scale Drug Substance Manufacturing: From a Continuous In Situ Nucleator to Free-Flowing Crystalline Particles},
  journal = {Crystals},
  year = {2023},
  volume = {13},
  number = {12},
  pages = {1675},
  doi = {10.3390/cryst13121675}
}
Kostenlos starten →